CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.
about
Chemical Lectinology: Tools for Probing the Ligands and Dynamics of Mammalian Lectins In VivoSiglecs as sensors of self in innate and adaptive immune responsesDendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle?B cell depletion reduces the number of autoreactive T helper cells and prevents glucose-6-phosphate isomerase-induced arthritisFrom a library of MAG antagonists to nanomolar CD22 ligands.Isolation of anti-CD22 Fv with high affinity by Fv display on human cells.Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivoA novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemiaTreatment of systemic lupus erythematosus with epratuzumab.Inotuzumab ozogamicin as novel therapy in lymphomas.CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing moleculeCharacterization of CD22 expression in acute lymphoblastic leukemiaEpratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II studyDistinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity.CD22 is required for formation of memory B cell precursors within germinal centers.Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphomaAnti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.Epratuzumab in the therapy of oncological and immunological diseases.B lymphocytes as therapeutic targets in systemic lupus erythematosus.IL-10-producing regulatory B cells (B10 cells) in autoimmune disease.A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.B-cell targeting: a novel approach to immune intervention today and tomorrow.Copresentation of antigen and ligands of Siglec-G induces B cell tolerance independent of CD22.FcgammaRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation.Basic and clinical immunology of SiglecsNovel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.Siglecs as targets for therapy in immune-cell-mediated disease.Besides an ITIM/SHP-1-dependent pathway, CD22 collaborates with Grb2 and plasma membrane calcium-ATPase in an ITIM/SHP-1-independent pathway of attenuation of Ca2+i signal in B cells.Characterization of the Highly Prevalent Regulatory CD24hiCD38hi B-Cell Population in Human Cord Blood.Emerging biotherapies for Sjögren's syndrome.B-cell-targeted therapies in systemic lupus erythematosusAnti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications.Siglec-8 and Siglec-F, the new therapeutic targets in asthma.Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.CD22 and autoimmune disease.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
P2860
Q26800514-C3697AD7-4216-4170-9613-94EA7D62DB7CQ26829757-54DE6C15-974B-4E11-A4E1-053F9D0A72A8Q27010312-E94F0AFC-E253-48A3-9B3F-815CF683BCD7Q28740546-2621848A-D9BC-4564-B741-3C5A2B527940Q31032076-F50C41AC-4530-4659-AD0B-530A8E6B34E6Q33246226-5AF8BE44-5A71-438D-A238-207E05EC5E8AQ33615157-A4FDA598-27A7-407A-82F1-55088BEF1E5BQ33758660-641286C7-71C3-448B-848E-BA4082F2CE91Q33883072-534A2D66-4924-4628-AFD3-892C819731E2Q34165735-0A07EB8D-AB14-4DB8-91E8-F042D3677E6DQ34580559-DD4AB58C-43DB-4C44-8FCA-D8A2A0AB1176Q34620271-A8F3EEF0-8B59-448F-9457-B9608863BF19Q35216815-B41080B4-323D-4C6E-B546-765031614EB6Q35514128-707D0D74-0EE1-4563-95BF-FE17A3A768CEQ35605535-DAF7CFAB-28E6-40F5-A91B-400C5F75FADFQ35950210-F17ECB3A-1187-42DD-9935-7ADBAFDE30A4Q36323954-32B964E3-B24F-440B-9B5B-A8BD6977F768Q36476080-18CE2074-D6B4-405B-B593-C30D18FF2574Q36484465-70FF1216-666D-4B5B-B468-7BCD633CD77FQ36569755-9113C4C3-9990-4BC0-BF7B-B8294F8DC888Q36619703-D9EFB83D-9DBD-4523-B9E0-29575D48F3F4Q36636619-6DA04135-E8B5-467C-9FAD-3735986F8F57Q36653646-970DB238-1325-4327-BA7A-3ECC63966841Q36760499-A04D6409-6738-4116-B25F-39B3160087B7Q36802757-CD716213-077C-4E33-A64C-944E74BAF52DQ36922233-84CC04F3-4E2F-4EA1-8C26-BD155FB1F37DQ37075803-ABA2D566-30CA-4BC1-B19E-2DFB3669AC19Q37100719-5C4C55AD-B5BC-4D5C-8A8F-3BBADE0C51B0Q37348437-583B04B1-17AB-4F83-854A-389E3A364E1CQ37370563-CD497EB7-3961-4F5C-B35F-479593C7C443Q37440061-701804C0-19B3-4916-97F6-55647637A8B2Q37636595-C910AF07-48DA-4441-ADC3-C484A1BD1FFEQ37683167-DAB26B60-3A59-497B-9098-A116A4264CBCQ37729176-656771EA-8888-4E01-879D-9E4460D29E1FQ37729368-3AFF2D07-FDB2-458D-9BEB-B29EDAAB43A8Q37823233-325A8450-6C35-40A9-820F-AAAAC566531FQ37983131-63FF90C2-5DC4-4857-8DB3-5E58718097A7Q38002447-55138932-5D76-4C4D-8BEB-48EDA1ABEB5DQ38053491-26DA0D34-FC81-4FDB-A414-B6F22489C0D0Q38068494-9CC9B9B5-C15E-4B6A-B67E-EE0E125B0325
P2860
CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
CD22: a multifunctional recept ...... vival and signal transduction.
@ast
CD22: a multifunctional recept ...... vival and signal transduction.
@en
type
label
CD22: a multifunctional recept ...... vival and signal transduction.
@ast
CD22: a multifunctional recept ...... vival and signal transduction.
@en
prefLabel
CD22: a multifunctional recept ...... vival and signal transduction.
@ast
CD22: a multifunctional recept ...... vival and signal transduction.
@en
P2093
P1476
CD22: a multifunctional recept ...... vival and signal transduction.
@en
P2093
Jonathan C Poe
Karen M Haas
Thomas F Tedder
P356
10.1016/S0065-2776(05)88001-0
P577
2005-01-01T00:00:00Z